Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
VX-670 in Myotonic Dystrophy Type I
NCT06926621Phase 2Enrolling by invitation
- Sponsor
- Vertex Pharmaceuticals
- Start
- Apr 2025
- Primary completion
- Jan 2029
- Countries
- 8
01
Overview
Phase 2, open-label, single-arm trial of VX-670 in myotonic dystrophy type 1 (DM1), sponsored by Vertex Pharmaceuticals. Primary endpoint: Number of Participants With Adverse Events (AEs) and Serious Adverse Events (SAEs) at 108 weeks. Started Apr 2025; status: enrolling by invitation.
02
Drugs
VX-670
03
Conditions
myotonic dystrophy type 1 (DM1)
Beyond the preview
Go deeper on NCT06926621.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT06926621.